{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:26:15Z","timestamp":1793924775778,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.vaccine.2026.129221","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:02:08Z","timestamp":1791428528000},"page":"129221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Circular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission"],"prefix":"10.1016","volume":"94","author":[{"given":"Nawapol","family":"Kunkeaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Nguitragool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitipa","family":"Thosapornvichai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattawut","family":"Buasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eizo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patompon","family":"Wongtrakoongate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jetsumon","family":"Sattabongkot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129221_bb0005","series-title":"World malaria report 2025","author":"World Health Organization","year":"2025"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129221_bb0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.pt.2022.05.006","article-title":"African plasmodium vivax malaria improbably rare or benign","volume":"38","author":"Baird","year":"2022","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2026.129221_bb0015","article-title":"Vivax malaria: a possible stumbling block for malaria elimination in India","volume":"11","author":"Kumar","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2026.129221_bb0020","series-title":"Global technical strategy for malaria 2016\u20132030, 2021 update","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.vaccine.2026.129221_bb0025","series-title":"Current topics and emerging issues in malaria elimination","article-title":"Elimination of plasmodium vivax malaria: problems and solutions","author":"Cui","year":"2021"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129221_bb0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/14760584.2021.1880898","article-title":"Progress towards the development of a P. vivax vaccine","volume":"20","author":"De","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129221_bb0035","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/BF03401770","article-title":"Sequence polymorphism in two novel plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates","volume":"4","author":"Tsuboi","year":"1998","journal-title":"Mol Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129221_bb0040","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1128\/IAI.68.12.6618-6623.2000","article-title":"Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of plasmodium vivax to infect mosquitoes","volume":"68","author":"Hisaeda","year":"2000","journal-title":"Infect Immun"},{"issue":"24","key":"10.1016\/j.vaccine.2026.129221_bb0045","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.vaccine.2004.12.019","article-title":"Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for plasmodium vivax malaria","volume":"23","author":"Malkin","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129221_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51","volume":"3","author":"Wu","year":"2008","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129221_bb0055","article-title":"Malaria vaccines: from the past towards the mRNA vaccine era","volume":"11","author":"Tsoumani","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"7810","key":"10.1016\/j.vaccine.2026.129221_bb0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41586-020-2220-1","article-title":"Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria","volume":"582","author":"Raj","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of plasmodium falciparum","volume":"7","author":"Hayashi","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41541-023-00783-y","article-title":"mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response","volume":"9","author":"Scaria","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41541-023-00786-9","article-title":"A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax","volume":"8","author":"Kunkeaw","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129221_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102645","article-title":"mRNA-LNP vaccine encoding the plasmodium vivax circumsporozoite protein is highly immunogenic and confers protection in mice","volume":"36","author":"Limsalakpetch","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.vaccine.2026.129221_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127971","article-title":"Value profile for malaria vaccines and monoclonal antibodies","author":"Birkett","year":"2025","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129221_bb0095","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.129221_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105370","article-title":"A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera","volume":"204","author":"Seephetdee","year":"2022","journal-title":"Antivir Res"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129221_bb0105","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","article-title":"N6-Methyladenosine modification controls circular RNA immunity","volume":"76","author":"Chen","year":"2019","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129221_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13060563","article-title":"Rational design and immunological mechanisms of circular RNA-based vaccines: emerging frontiers in combating pathogen infection","volume":"13","author":"Zhang","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129221_bb0120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129221_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102687","article-title":"The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases","volume":"36","author":"Chen","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129221_bb0130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ymthe.2025.10.038","article-title":"CircRNA: unlocking new frontiers in therapeutic and vaccine development","volume":"34","author":"Bahrulolum","year":"2026","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129221_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines14090781","article-title":"Research progress, application, and industrialization prospects of circular RNA vaccines in viral diseases","volume":"14","author":"Cai","year":"2026","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129221_bb0140","article-title":"Circular RNA as a new vaccine platform: considerations, challenges, and perspectives","volume":"14","author":"Lee","year":"2026","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","article-title":"Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals","volume":"180","author":"Kreiter","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10709","article-title":"MHCI trafficking signal-based mRNA vaccines strengthening immune protection against RNA viruses","volume":"10","author":"Zhang","year":"2025","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0155","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129221_bb0160","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.vaccine.2012.01.003","article-title":"Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate","volume":"30","author":"Tachibana","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129221_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102954","article-title":"Comparative analysis of expression, immunogenicity, and safety profiles between linear and circular RNA vaccine platforms","volume":"37","author":"Lee","year":"2026","journal-title":"Mol Ther Nucleic Acids"},{"issue":"38","key":"10.1016\/j.vaccine.2026.129221_bb0170","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2505718122","article-title":"Circular RNA lipid nanoparticle vaccine against SARS-CoV-2","volume":"122","author":"Swingle","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129221_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113498","article-title":"Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2","volume":"28","author":"Singh","year":"2025","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129221_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines14040315","article-title":"Comparison of vaccine platforms for Machupo virus","volume":"14","author":"Erickson","year":"2026","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129221_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1670350","article-title":"The mRNA component of LNP-mRNA vaccines triggers IFNAR-dependent immune activation which attenuates the adaptive immune response","volume":"16","author":"Bar-On","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129221_bb0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-025-01362-z","article-title":"Type I interferon restricts mRNA vaccine efficacy through suppression of antigen uptake in cDCs","volume":"11","author":"Lobb","year":"2026","journal-title":"NPJ Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129221_bb0195","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1006\/mthe.2000.0050","article-title":"IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector","volume":"1","author":"Mizuguchi","year":"2000","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129221_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11020238","article-title":"Cap-independent circular mRNA translation efficiency","volume":"11","author":"Deviatkin","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129221_bb0205","doi-asserted-by":"crossref","first-page":"1106369","DOI":"10.3389\/fcimb.2022.1106369","article-title":"Naturally acquired antibodies to gametocyte antigens are associated with reduced transmission of plasmodium vivax gametocytes to Anopheles arabiensis mosquitoes","volume":"12","author":"Tebeje","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129221_bb0210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/infdis\/jiad469","article-title":"Naturally acquired transmission-blocking immunity against different strains of plasmodium vivax in a malaria-endemic area in Thailand","volume":"229","author":"Thongpoon","year":"2024","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:53:28Z","timestamp":1793922808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26010303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":42,"alternative-id":["S0264410X26010303"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129221","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129221"}}